Human Papillomavirus (HPV) Vaccines Industry, Forecast to 2032 - HPV Vaccine Market Set to Nearly Triple by 2032 as U.S. & Europe Lead; Japan & India Emerge as Key Growth Regions
07 nov. 2024 09h33 HE
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Human Papillomavirus (HPV) Vaccine Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The human...
Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer
05 nov. 2024 09h01 HE
|
Nouscom Srl
Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well...
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way
14 oct. 2024 11h48 HE
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "mRNA Cancer Vaccines and Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The mRNA cancer vaccines and...
Cancer Vaccines Market Forecasts from 2024 to 2029: Lung and Breast Cancer Remain Key Targets, FDA Approvals for HPV and HBV Vaccines Boost Expansion
11 oct. 2024 06h49 HE
|
Research and Markets
Dublin, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The "Global Cancer Vaccines Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The global cancer vaccine...
Nouscom to Present Updated Positive Data on NOUS-209’s Potential to ‘Intercept’ Cancer in Lynch Syndrome Carriers at SITC 2024
04 oct. 2024 09h00 HE
|
Nouscom Srl
BASEL, Switzerland – 4th October 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announces...
Cancer Vaccines Industry Research Report 2024: Market Poised for Exponential Growth with a Projected Value of $6.7 Billion by 2032
05 sept. 2024 10h47 HE
|
Research and Markets
Dublin, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The "Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's...
Cancer Vaccines Global Strategic Market Report 2023-2030: Development of Novel Cancer Vaccines, and Favorable Government Initiatives and Funding Bodes Well for the Industry
28 août 2024 05h34 HE
|
Research and Markets
Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "Cancer Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer Vaccines...
Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice President, Technical and CMC Development
17 juil. 2024 03h00 HE
|
Nouscom Srl
BASEL, Switzerland – 17th July 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today...
Global mRNA Cancer Vaccines Clinical Trials Market Report 2024: First Commercial mRNA Vaccine Approval Expected by 2029
12 juin 2024 07h32 HE
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global mRNA Cancer Vaccines Clinical Trials & Market Future Outlook 2024" drug pipelines has been added to ResearchAndMarkets.com's...
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
14 mai 2024 03h00 HE
|
Nouscom Srl
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that...